Shots: The companies have completed the enrolment in P-II AKI-002-15 study evaluating the safety and efficacy of ANG-3777 (2.0 mg/kg, IV) vs PBO over 4 days in patients with CSA-AKI […]readmore
Tags : Acute Kidney Injury
Shots: The US FDA has granted FT designation to the development of ASP1128 for patients at increased risk of developing moderate to severe acute kidney injury (AKI) after coronary artery […]readmore
Shots: Baxter has received the US FDA’s 510 (k) clearance for its PrisMax system and the integrated TherMax blood warmer for continuous renal replacement therapy (CRRT) and therapeutic plasma exchange […]readmore
Shots: Baxter and BioMerieux enter into an agreement to develop biomarkers for identification & treatment for acute kidney injury (AKI) The focus of the agreement is to utilize BioMerieux’s expertise […]readmore